NCT07332000 2026-03-17
A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
Candel Therapeutics, Inc.
Phase 2 Recruiting
Clinical Trials
82 trialsNCT04300556 2026-03-13
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT05968326 2026-03-12
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT06901531 2026-03-11
LUCERNA
Astellas Pharma Inc
Phase 3 Recruiting
NCT06902545 2026-03-11
A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction Cancer.
Astellas Pharma Inc
Recruiting
NCT06957691 2026-03-09
Fezo-ADT
Brigham and Women's Hospital
Phase 2 Recruiting
NCT07182279 2026-03-09
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT05672524 2026-03-04
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05873686 2026-03-03
A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Phase 1 Recruiting
NCT04605913 2026-02-25
Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC
Mayo Clinic
Phase 1/2 Recruiting
NCT05581121 2026-02-25
PAROLA
Institut Claudius Regaud
Phase 3 Recruiting
NCT07124000 2026-02-24
DP-04
AstraZeneca
Recruiting
NCT07431281 2026-02-24
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04379596 2026-02-23
DG-03
AstraZeneca
Phase 2 Recruiting
NCT07259317 2026-02-20
Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Corcept Therapeutics
Phase 2 Recruiting
NCT05922930 2026-02-19
Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT06616597 2026-02-19
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT07115914 2026-02-17
PSMA PET for Surveillance After Focal Therapy
University of Chicago
Phase NA Recruiting
NCT07407608 2026-02-12
ABRUPT 2
University of Milano Bicocca
Recruiting
NCT07023315 2026-02-11
A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma
Akeso
Phase 3 Recruiting
NCT00349830 2026-02-10
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Stanford University
Recruiting
NCT06834152 2026-02-09
X-SMILE
University of Zurich
Recruiting
NCT07196488 2026-02-09
Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses
National Taipei University of Nursing and Health Sciences
Phase NA Recruiting
NCT06631521 2026-02-05
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
AdventHealth
Phase 1 Recruiting
NCT07370597 2026-01-27
LUDOPATH
Jules Bordet Institute
Recruiting
NCT07363382 2026-01-23
The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer
First Affiliated Hospital of Fujian Medical University
Phase 1/2 Recruiting
NCT05620628 2026-01-21
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
Samsung Medical Center
Phase 2 Recruiting
NCT05208944 2026-01-20
THIO Sequenced With Cemiplimab in Advanced NSCLC
Maia Biotechnology
Phase 2 Recruiting
NCT07284186 2026-01-16
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Plexium, Inc.
Phase 1 Recruiting
NCT07344844 2026-01-15
SPAR
Clinique Sainte Clotilde
Phase NA Recruiting
NCT06592924 2026-01-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT07339943 2026-01-14
MicroUSgFLA
University Health Network, Toronto
Phase NA Recruiting
NCT06908304 2026-01-12
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Maia Biotechnology
Phase 3 Recruiting
NCT07129551 2026-01-12
NICE-PSMA
Martini-Klinik am UKE GmbH
Phase NA Recruiting
NCT06782932 2025-12-03
Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Recruiting
NCT06846346 2025-11-28
GRACIE
UNICANCER
Phase 2 Recruiting
NCT06046131 2025-11-17
KP-CARAIBES
Centre Hospitalier Universitaire de la Guadeloupe
Phase NA Recruiting
NCT06862856 2025-11-13
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
Massachusetts General Hospital
Recruiting
NCT06844383 2025-10-29
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT07219303 2025-10-29
DE-CART
Fox Chase Cancer Center
Phase NA Recruiting
NCT07218003 2025-10-24
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Rondo Therapeutics
Phase 1 Recruiting
NCT06800313 2025-10-16
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Halda Therapeutics OpCo, Inc.
Phase 1/2 Recruiting
NCT07209878 2025-10-07
68Ga-PSMA-11 PET Imaging for Diagnosing Prostate Cancer, a Head-to-head Comparison With mpMRI
First Affiliated Hospital of Fujian Medical University
Phase 2/3 Recruiting
NCT04361708 2025-10-01
I-FLOAT
University of Chicago
Phase 1 Recruiting
NCT05116072 2025-09-25
TPIAT-01
University Hospital, Lille
Phase 1/2 Recruiting
NCT07179783 2025-09-18
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
Tianjin Medical University Second Hospital
Phase 2 Recruiting
NCT07018570 2025-08-26
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma
National Cancer Center Hospital East
Phase 2 Recruiting
NCT06605404 2025-08-14
Pan-tumor MRD Study
Paradigm Health
Recruiting
NCT07098026 2025-08-01
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
Hunan Cancer Hospital
Phase NA Recruiting
NCT04069273 2025-07-31
SEQUEL
Hoosier Cancer Research Network
Phase 2 Recruiting